AbbVie got FDA approval for antibiotic treatment Emblaveo. Regeneron’s Linvoseltamab BLA was accepted ... Fallon Capital Management pressed Astellas Pharma to cut costs and overhaul drugs research.
Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...
Drugmaker AbbVie announced late last week that the US Food and Drug Administration (FDA) has approved Emblaveo ...
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited ...
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEOâ„¢ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback